Zhitong Financial APP, Shu Taishen (300204.SZ) notice, the company received the U. S. Food and Drug Administration (FDA) notice to accept STSA-1002 hypodermic injection on ANCA-associated vasculitis indications of new drug clinical trial application.
It is reported that STSA-1002 is a recombinant anti-human C5aIgG1 monoclonal antibody targeting C5a. By specifically binding to allergic toxin C5a, C5a loses its ability to bind to the receptor and blocks C5a-induced biological functions, such as neutrophil chemotaxis, degranulation and oxygen respiratory burst, while not affecting C5 cleavage and membrane attack complex (MAC) formation, retaining the bacteriolytic and bactericidal function of the complement system.
